Differential glucose uptake by endothelial cells in response to in-vitro Herpes Virus 8 infection, when challenged with serums from diabetes mellitus type 2 patients

1. Problem Statement

The study addresses the emerging hypothesis that Human Herpesvirus 8 (HHV8), an oncogenic virus known to cause Kaposi's sarcoma (KS), may also play a causal or contributory role in the pathogenesis of Type 2 Diabetes Mellitus (DM2). While previous research established that HHV8 infects endothelial cells and alters their metabolism (specifically increasing insulin receptor expression and glucose consumption), the interaction between HHV8-infected cells and the systemic environment of diabetic patients remains unclear. Specifically, the authors sought to determine how serums from DM2 patients (both HHV8-positive and HHV8-negative) differentially affect glucose uptake in infected versus uninfected human endothelial cells.

2. Methodology

The researchers utilized an in vitro model using Human Umbilical Vein Endothelial Cells (HUVEC).

• Cell Culture & Infection: HUVECs were infected with HHV8. To induce viral reactivation from latency to the lytic phase, 12-O-tetradecanoylphorbol-13-acetate (TPA) was added to the culture medium 10 days post-infection.
• Serum Treatment: Cells were divided into groups and treated with serums from:
  • Diabetic Patients (DM2): Categorized as HHV8-positive (lytic phase), HHV8-positive (latent phase), or HHV8-negative.
  • Controls: Non-diabetic individuals (HHV8-positive and HHV8-negative).
  • Serums were added at a 5% concentration.
• Glucose Uptake Assay:
  • Cells were incubated in glucose-free medium for 60 minutes.
  • Human insulin (1/1000 dilution) was added to stimulate uptake.
  • Tracer: 0.7 mCi/ml of tritiated 2-deoxy-D-glucose (H3-2-DD-glucose) was added for 15 minutes.
  • Measurement: Cells were lysed, and radioactivity (Counts Per Minute - CPM) was measured via scintillation counting to quantify glucose uptake.

3. Key Contributions

• Dual-Effect Discovery: The study demonstrates a paradoxical, dual-effect mechanism where HHV8 infection fundamentally alters cellular response to diabetic serums.
  • In uninfected cells, DM2 serums suppress glucose uptake (mimicking insulin resistance).
  • In HHV8-infected cells, DM2 serums (especially those positive for HHV8) significantly enhance glucose uptake beyond the baseline increase caused by the virus alone.
• Phase-Specific Impact: The study distinguishes between the effects of serums containing antibodies against the lytic versus latent phases of HHV8, finding that lytic-phase serums induce the most dramatic changes.
• Hypothesis Generation: The authors propose a novel mechanism where anti-HHV8 antibodies in the serum bind to viral antigens on infected cells, triggering hyper-metabolism in those cells while simultaneously starving uninfected cells of glucose, potentially driving systemic hyperglycemia.

4. Results

The data revealed statistically significant differences (p < 0.01 or p < 0.05) across the experimental groups:

• Uninfected HUVECs (Control):

  • Baseline glucose uptake was set at 100%.
  • Treatment with DM2 serums caused a significant decrease in glucose uptake:
    • HHV8-positive (Lytic) serum: ~53% reduction (D1).
    • HHV8-positive (Latent) serum: ~16% reduction (D2).
    • HHV8-negative DM2 serum: ~28% reduction (D3).
  • Interpretation: This confirms that DM2 serums induce an insulin-resistant phenotype in normal endothelial cells.

• HHV8-Infected HUVECs:

  • Baseline infected cells (without DM2 serum) showed ~180-195% glucose uptake compared to uninfected controls, confirming the virus's ability to upregulate glucose metabolism.
  • Treatment with DM2 serums caused a further dramatic increase:
    • HHV8-positive (Lytic) serum: ~294% uptake (a ~50% increase over the infected baseline).
    • HHV8-positive (Latent) serum: ~261% uptake (a ~33% increase).
    • HHV8-negative DM2 serum: ~227% uptake (a ~16% increase).
  • Interpretation: The presence of anti-HHV8 antibodies in diabetic serums synergistically amplifies the virus-induced glucose hyper-consumption.

5. Significance and Conclusion

• Mechanistic Insight: The study suggests that HHV8 infection may be a specific initiating event for Type 2 Diabetes in a subset of patients (estimated at ~50% in the authors' region). The virus upregulates Insulin Receptors (IR) on endothelial cells; when exposed to the specific immune environment of a diabetic patient (containing anti-HHV8 antibodies), these cells become "glucose sinks," aggressively consuming glucose.
• Systemic Consequence: This localized hyper-consumption by infected cells, coupled with the suppression of glucose uptake in uninfected cells (due to the same serum factors), creates a systemic state of hyperglycemia and insulin resistance.
• Clinical Implications: The findings challenge the purely metabolic view of DM2, suggesting a viral-immunological etiology for a significant portion of cases. It implies that screening for HHV8 status and managing viral reactivation could be relevant in diabetes treatment strategies.
• Future Directions: The authors call for further investigation into the specific molecular mechanisms by which anti-HHV8 antibodies modulate glucose transport systems and the potential for targeting this viral-metabolic axis in therapy.

Note: This summary is based on a bioRxiv preprint (posted March 3, 2026) which has not yet undergone peer review.